Cognition Therapeutics, Inc. (NASDAQ:CGTX) Short Interest Up 46.7% in April

Cognition Therapeutics, Inc. (NASDAQ:CGTX - Get Free Report) was the target of a large growth in short interest in the month of April. As of April 15th, there was short interest totalling 220,300 shares, a growth of 46.7% from the March 31st total of 150,200 shares. Currently, 0.7% of the company's stock are sold short. Based on an average trading volume of 200,700 shares, the days-to-cover ratio is presently 1.1 days.

Institutional Trading of Cognition Therapeutics

A number of institutional investors have recently made changes to their positions in the business. Sigma Planning Corp acquired a new stake in Cognition Therapeutics during the 4th quarter worth about $53,000. Steward Financial Group LLC purchased a new position in shares of Cognition Therapeutics during the 3rd quarter valued at about $58,000. Texas Capital Bank Wealth Management Services Inc purchased a new position in shares of Cognition Therapeutics during the 4th quarter valued at about $102,000. Finally, Twin Focus Capital Partners LLC purchased a new position in shares of Cognition Therapeutics during the 4th quarter valued at about $173,000. Institutional investors and hedge funds own 43.35% of the company's stock.

Analyst Ratings Changes

CGTX has been the topic of a number of analyst reports. B. Riley reiterated a "buy" rating and issued a $5.00 price target on shares of Cognition Therapeutics in a report on Thursday, March 28th. Oppenheimer reiterated an "outperform" rating and issued a $9.00 price target on shares of Cognition Therapeutics in a report on Wednesday, March 27th.

Cognition Therapeutics Stock Up 1.0 %

Shares of Cognition Therapeutics stock traded up $0.02 during trading on Friday, reaching $1.95. The company's stock had a trading volume of 55,056 shares, compared to its average volume of 129,695. The company has a market cap of $76.05 million, a price-to-earnings ratio of -2.27 and a beta of 1.63. Cognition Therapeutics has a 1-year low of $0.90 and a 1-year high of $3.49. The company has a 50-day simple moving average of $1.93 and a two-hundred day simple moving average of $1.74.

Cognition Therapeutics (NASDAQ:CGTX - Get Free Report) last posted its quarterly earnings data on Tuesday, March 26th. The company reported ($0.27) earnings per share for the quarter, topping analysts' consensus estimates of ($0.38) by $0.11. As a group, analysts anticipate that Cognition Therapeutics will post -0.98 earnings per share for the current year.

About Cognition Therapeutics

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex for the treatment of Alzheimer's disease.